We studied the value of leukocyte depletion of platelet trans fusions for the prevention of secondary human leukocyte antigen (HLA)-alloimmunization in patients with a high-risk of prior immunization induced by pregnancies. Seventy-five female patients with hematologic malignancies (mostly acute leukemia) and a history of pregnancy were random ized to receive either standard random single-donor platelet transfusions (mean leukocytes, 430 x 10s per transfusion) or leukocyte-depleted random single-donor platelet transfu sions. Leukocyte depletion to less than 5 x10s leukocytes per platelet transfusion (mean leukocytes, 2 x 10° per trans fusion) was achieved by filtration. Of the 62 evaluable pa tients, refractoriness to random donor platelets occurred in 41% (14 of 34) of the patients in the standard group and in 29% (8 of 28) of the patients in the filtered group (P = .52); anti-HLA antibodies developed in 43% (9 of 21) of individuals in the standard group and 44% (11 of 25) of cases in the filtered group. The tim e toward refractoriness and develop ment of anti-HLA antibodies was similar for both groups. We conclude that leukocyte depletion of random single-donor platelet products to less than 5 x 10® per transfusion does not reduce the incidence of refractoriness to random donor platelet transfusions because of boostering of anti-HLA anti bodies. © 1995 by The American Society of Hematology.
R EFRACTORINESS to random donor platelets caused sions containing less than 20 X 106 leukocytes per transfuby alloimmunization occurs in 30% to 50% of pa tients.1'3 The antibodies involved are mostly directed against human leukocyte antigens (HLAs). Procedures to provide alloimmunized patients with platelets obtained from HLAmatched donors4 or alternatively from donors selected by a response occurred that was not prevented by the degree of platelet crossmatch5 are logistically complicated, costly, and leukocyte depletion applied, still 10% to 30% of these transfusions are unsuccessful/'
sion, it was observed that the incidence o f HLA-alloimmunization was not decreased in patients with previous pregnancies in contrast with nonpresensitized patients.10 This suggests that a secondary (or booster) anti-HLA immune
This explains the interest for developing methods to prevent alloimmunization.
Studies both in rats and in mice have shown that pure
It is the aim o f the present study to investigate the role of more vigorous leukocyte depletion of platelet suspensions, ie, less than 5 X 106 leukocytes per transfusion for the pre vention o f the secondary anti-HLA immune response. Thereplatelets do not provoke a primary immune response.7,8 This fore, only females with previous pregnancies were the subsuggests that primary HLA-alloimmunization after platelet jects of a prospective randomized controlled study that was transfusions is caused by the leukocytes contaminating the platelet suspension. A nonrandomized retrospective study in humans indeed suggested that leukocyte depletion o f platelet transfusions reduced the development of HLA-alloimmuni-conducted in four centers. Random single-donor platelet transfusions were used exclusively because it has been docu mented that the use o f this non-leukocyte-depleted product might postpone the development o f alloimmunization, 13, 14 MATERIALS AND METHODS zation.9 In further randomized and/or prospective studies, especially in patients with previous pregnancies, it was confirmed that leukocyte depletion o f both platelet transfusions and red blood cell (RBC) products resulted in a decreased frequency of HLA-alloimmunization,2,3,1<1'11 in particular, the incidence of the primary anti-HLA immune response.11,12 In a nonrandomized prospective study on the value o f leukocyte-depleted multiple donor platelet transfu- 14 
P atients
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Patients were eligible for entry into the study when they fulfilled all of the following criteria: (1) untreated hematologic malignancy;
(2) history of previous pregnancies; (3) no blood transfusions re ceived in the past 6 weeks except for filtered RBCs; and (4) transient thrombocytopenia caused by bone marrow (BM) failure. Seventyfive patients were randomized and stratified by hospital to receive either standard random single-donor platelets (standard group) or random single-donor platelets leukocyte depleted by filtration (fil tered group). Patients remained on study until one of the following events occurred: (1) refractoriness to random single-donor platelets; (2) death; or (3) BM transplantation. 
Preparation o f Blood Components and Transfusion
Single-dorior platelet concentrates.
Single-donor platelets were collected by hemapheresis using discontinuous flow centrifugation (Haemonetics, V50, surge-protocol). Patients in the standard group received the platelet suspensions without further processing. For the preparation of leukocyte-depleted platelet products, platelet suspen sions were filtered through a cellulose acetate filter (Cellselect; NPBI, Emmer-Compascuum, The Netherlands) designed for filtra tion of RBC. This filter has been shown to be efficient for the removal of leukocytes from platelet suspensions provided that the platelets are inactivated during filtration either by adding ACD-A to lower the pH to 6.5 to 6.8, or 12.5 fig prostacylin to the platelet suspension before filtration.1'' Filtration was performed within 36 hours after collection to reduce the risk of immunization by leuko cyte fragments. After filtration, the platelets were transfused immedi ately. Standard platelets were also transfused within 36 hours after collection. Platelet products were routinely irradiated (20 Gy) in one center.
The platelet and leukocyte contents of standard and filtered platelet products are shown in Table 1 . Platelet and leukocyte counts préfil tration were established automatically (different types of analyzers per center). Leukocyte counts postfiltration were counted manually using a 1/10 dilution of the blood sample with TUrk Solution and a Fuchs Rosenthal chamber. The detection limit of this method is » 5 x lO'VL leukocytes, which corresponds to x H)'1 leukocytes per platelet transfusion.
Transfusion regimen. ABO-compatible platelets were transfused prophylactically when the platelet count dropped below 10 to 20 X 10'VL, or therapeutically for invasive procedures and in case of major hemorrhagic symptoms at platelet counts above 10 to 20 X 10'VL. No granulocyte transfusions were administered.
Assessment of platelet recovery and definition of refractori ness, Posttransfusion platelet recoveries were performed I hour and 16 to 20 hours after the platelet transfusion. Platelet recovery was calculated according to the following formula:
Absolute Increment X Blood Volume Recovery (%) = 100 X No. of Transfused Platelets
Blood volume was calculated as body surface area (n r) X 2.5. No correction for splenic pooling was made.
Patients were considered refractory to random single-donor plate let transfusions when one of the following occurred: (1) two consecu tive platelet transfusions with I-hour posttransfusion platelet recov eries of less than 20% in the absence of clinical factors known to adversely affect platelet recovery (temperature > 38.5°C, septicemia, disseminated intravascular coagulation [DfC] or splenomegaly); or (2) a single platelet transfusion with 1-hour posttransfusion platelet recovery of less than 20% in the presence of anti-HLA antibodies.
Anti-HLA antibody screening. Sera were collected at entry and at weekly intervals during a transfusion period and on clinical indica tion, ie, in case of poor posttransfusion platelet recoveries. Final serum samples were obtained 2 to 4 weeks after the last transfusion. Sera were stored at -7Q°C until testing, Each serum was tested in the complement-dependent lymphocytotoxicity test17 against a panel of 2 1 selected donors covering most of the defined I-1LA-A and HLA-B specificities. The screening test was considered positive when at least 10% of the panel cells showed cytotoxicity (>50% dead cells per well).
Statistical analysis. The occurrence of clinical refractoriness and the development of anti-HLA antibodies were analyzed as a function of time and the number of transfusions received using the actuarial method of Kaplan-Meijer. The log-rank test was applied to test for differences between the two treatment groups. Cox proportional hazard model was used to calculate the relative risk of developing refractoriness or HLA antibodies in the filtered group as compared with the standard group with 95% confidence limits (CLs). The Mann-Whitney U test was used to test for differences between the percentages panel reactive antibodies of the two groups.
RESULTS
Patients
Thirteen patients were excluded from evaluation because: (1) anti-HLA antibodies were present at entry (n = 4); (2) less than two transfusions were administered (n = 7); (3) administration of blood products other than filtered RBCs in the period of 6 weeks preceeding entry (n = 3). The characteristics of the 62 evaluable patients are shown in Table 2 . No statistically significant differences were apparent between the groups with regard to age, diagnosis, number of previous pregnancies, and history o f previous transfusions.
P rotocol Violations
During the study period, pooled leukocyte-depleted (fil tered) random multiple-donor platelet concentrates were by error administered on 14 occasions: 8 transfusions into 6 patients in the standard group; 6 transfusions into 4 patients in the filtered group. Of these 10 patients, 3 became refrae- 
Table2. Platelet Products
tory after this protocol violation: 2 patients in the standard group and 1 patient in the filtered group. Exclusion of these patients from analysis from the moment of receiving a ran dom multiple-donor transfusion would not have altered the outcome of the analysis (data not shown).
Eight patients in the filtered group received a total number of 11 platelet products containing greater than 5 X 106 leuko cytes. Two of these patients became refractory. The number of leukocytes in the four transfusions administered to these two patients varied from 5.1 X 106 to 7.0 X 106 leukocytes with the exception of one transfusion containing 20 X 106 leukocytes.
Development o f Refractoriness and HLA-Alloimmunization
Refractoriness. In this study, 671 random single-donor transfusions were administered during the study period in both groups. Recovery data were available in 592/671 (88%) transfusions at 1 hour and in 576/671 (86%) transfusions at 16 to 20 hours posttransfusion. In 643/671 transfusions o f refractoriness and the time interval to develop refractori ness. When the patients in the filtered group were censored from the moment o f receiving a platelet product containing more than 5 X 106 leukocytes, the difference between the two groups was also not statistically significant (log-rank P = .32). With the Cox proportional hazard model, using the number o f days until refractoriness or until the last transfu sion as time variable, the relative risk of becoming refractory in the filtered group as compared with the standard group was 0.75 (95% CL: 0.31, 1.8) . This corresponds to a 9% reduction in the actuarial probability of becoming refractory (95% CL: -21% , +31%). 5 (95% CL: 0.6, 3.7) . This correrecovery (temperature >38.5°C: n = 2, DIC: n = 1) were sponds to an increase in the actuarial probability of develpresent; in the sera of these 3 patients, anti-HLA antibodies oping anti-HLA antibodies o f 14% (95% CL: -16% , +42%, were demonstrable. (2) in five patients, a 1-hour posttransfu-Cox proportional hazard model). With regard to the reactivsion platelet recovery of less than 20% occurred once in the ity pattern of the anti-HLA antibodies, the median percentage presence of anti-HLA antibodies. panel reactive antibodies (PRA) at the time of seroconver-In Fig 1, A and B , the development o f refractoriness for sion in the filtered group was 24% (range, 10 to 67) and in the two groups is shown. In the standard group, 14/34 (41%) the standard group 43% (range, 10 to 100). This difference patients became refractory, versus 8/28 (29%) patients in was statistically not significant (P = .65, Mann-Whitney U the filtered group. Actuarial analysis using the log rank test test). Sera contained multispecific anti-HLA antibodies with showed that this difference was not statistically significant the exception o f sera from five patients in which HLA-speci-(P = .52). This type of analysis includes both the incidence ficities were identified. Sera o f four patients in the filtered group showed HLA specificities: anti-B5 (10% PRA); anti-B7 (24% PRA); anti-A2 + B44 (67% PRA); and anti-A3 + B5 (19% PRA). In the standard group, only in one patient anti-Al was identified (52% PRA). Of the 22 refractory patients, five were considered refrac tory because a single transfusion failure was associated with the presence of anti-HLA antibodies. Fifteen of the re maining 17 refractory patients were evaluable for anti-HLA antibodies: in 13 of these 15 (87%), anti-HLA antibodies were detected. In 35 of the 40 nonrefractory patients, the presence of anti-HLA antibodies could be evaluated: in 11 of these 35 patients (31%), anti-HLA antibodies were detected.
HLA-alloimmunization. From
DISCUSSION
The present study shows that in patients with previous pregnancies, leukocyte depletion o f random single-donor platelet transfusions to less than 5 X I O'1 leukocytes per transfusion does not reduce the incidence o f platelet refracto riness and anti-HLA antibodies. In »40% of the patients studied, anti-HLA alloantibodies developed irrespective of whether platelet products were leukocyte depleted or not. There are several arguments indicating that in the majority of patients the development o f anti-HLA antibodies resulted from a secondary anti-HLA immune response. Firstly, the frequency of 40% HLA-alloimmunization after transfusion of filtered blood products observed in this study is much higher than has been found in patients at risk for primary HLA-alloimmunization of whom only 11 % developed anti-HLA antibodies after leukocyte-depleted transfusions.11 Sec ondly, it has been shown that 40% of females in second or further pregnancy develop anti-HLA antibodies,18*19 which transfusion o f blood containing leukocytes sharing at least the case, although it cannot be excluded that small numbers of leukocytes that were below detection level have been present in the transfusion products used in these studies. To test this hypothesis, further studies are needed with blood products containing even less contaminating leukocytes, eg, less than 104 per transfusion. Such a study would require both the availability of new blood filters with increased leukocyte removal capacity that are currently being developed21 and also the development o f methods that allow enumeration of the very low number o f leukocytes remaining postfiltration, eg, by PCR. Also based on animal studies, soluble HLA-antigens or microparticles escaping leukocyte filtration may evoke plate let refractoriness.22,2'' In humans, Pellegrino et al24 found that transfusion o f plasma that contains leukocyte fragments from selected donors resulted in the onset of anti-HLA antibodies. As our patients received blood products that contained plasma, it cannot be excluded that this might have had a role in the stimulation of anti-HLA antibodies.
Another approach to reduce secondary HLA-alloimmuni zation is the use of UV-irradiation of blood products. Prelim inary data from animal and clinical studies suggest that UV irradiation might reduce primary HLA-alloimmunization, while in vitro data suggest that the secondary immune re sponse may be prevented.25,26 It was suggested in animal studies that UV-B irradation is superior to leukocyte deple tion in the prevention o f the immune response. 27 Finally, it might be worthwile to explore strategies based on other mechanisms to modify the immune response. Stud ies in renal transplantation patients have shown that the is in close agreement with the frequency of anti-HLA anti bodies found in this study. Thirdly, in both study groups, anti-HLA antibodies occurred in 50% of the alloimmunized patients within 2 weeks o f the first transfusion. This is con siderably faster than in primary HLA-one HLA-DR antigen between donor and recipient results in reduced incidence of primary t by a state of immune unres transfusions.28 Whether this mis mate zation where this took a median o f 8 to 16 weeks for patients receiving filtered platelet products ( < 5 X 10f> and a median of 4 weeks for patients in the control group (mean number of leukocytes, 35 X 106).11
Previous studies have identified women with pregancies as patients with an increased risk for HLA-alloimmunization. When leukocyte-depleted platelet transfusions, which con tain, on average, 46 X l(V' leukocytes, were administered, 6 o f 8 patients with previous pregnancies became refractory versus none of 17 nonpresensitized patients.20 Previously, it had been shown that platelet transfusions containing less than 20 X I O'1 leukocytes induced refractoriness in 15 of 71 (21%) of females with previous pregnancies, whereas this occurred in only 16 of 264 (6%) nonpresensitized patients.1(1 In the present study, leukocyte depletion was more vigourous and we have now shown that platelet products containing less than 5 X 10° leukocytes (mean, 2 X H)'1) do not result in a reduction of the frequency of refractoriness and HLAalloimmunization nor in the time required to become refrac tory or develop HLA-alloimmunization.
An explanation for this finding may be that platelets per ss to further menon could be applied for the prevention of a secondary immune re sponse remains to be elucidated.
In conclusion, it is now well established that primary HLA-alloimmunization caused by transfusions of RBCs and platelets can be prevented when the number of leukocytes is reduced below the threshold for alloimmunization by leu kocyte depletion of the blood products. Although the number of leukocytes that will lead to a primary immune response is not precisely known, presently available blood bank tech nology, especially filtration, will allow the routine prepara tion of blood products with a degree of leukocyte depletion sufficient to prevent primary HLA-alloimmunization. A sub group o f patients now remains for whom the use of leuko cyte-depleted transfusions does not reduce the incidence of alloimmunization, ie, women with previous pregnancies. Hence, future studies dealing with the prevention of transfu sion-induced HLA-alloimmunization should focus on this category of patients.
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